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Most treatment decisions in oncology are 
still based on histomorphological crite-
ria, criteria that are incorporated in actual 
staging systems. With just a few exceptions 
(i.e., leukemias, some lymphomas, GIST, 
NSCLC, etc.) molecular and immunologi-
cal characteristics of individual tumors do 
not contribute to this process. The basis for 
clinical considerations and treatment indi-
cations are clinical trials. In these clinical 
trials, a specific treatment is associated with 
a statistical outcome for the entire patient 
population treated in this trial. Not surpris-
ingly, a subgroup of patients does not ben-
efit from the administered treatment and 
no biomarker to identify these patient sub-
populations have been found. So treatment 
recommendations are typically given as rec-
ommendations for all patients with compa-
rable disease situations. As an example, we 
treat patients with adjuvant chemotherapy 
knowing that a small minority, far less than 
20% of all treated patients, benefits from 
such adjuvant treatments. The vast major-
ity experiences only treatment related side 
effects. In parallel, this approach produces 
enormous costs for our health care system. 
In advanced disease situations, treatments 
leading to objective response rates of 30% 
and higher are considered to be effective 
treatments. Still, the majority of patients 
does not benefit and experiences treat-
ment related side effects compromising 
their quality of life.
How to change this situation? In oncol-
ogy, most systemic treatments consist of 
chemotherapy as single agent or combina-
tion treatment. We have not really under-
stood why such treatments are effective 
only in some patients and while other 
patients progress under the same treat-
ment. The era of gene expression profiling 
has not convincingly contributed to a bet-
ter understanding of the individual tumor 
biology or reproducible molecular profiles 
with predictive value. With some excep-
tion for breast cancer, the characterization 
of “treatment responsive” versus “treatment 
resistant” tumors is not possible. The great 
hope of the oncology community is now 
that genome profiling and sequencing will 
give us more valuable insights into misregu-
lated pathways driving tumor growth and 
metastases and a subsequent personalized 
approach to specifically target these altera-
tions with novel drugs (Stratton, 2011).
It becomes more and more accepted that 
the fate of an individual tumor patient not 
only depends on the molecular character-
istics of the tumor, the prognosis is also 
strongly influenced by tumor–host immune 
interactions. This has convincingly been 
shown for colon cancer and non-small cell 
lung cancer by Fridman and Galon (Zhang 
et al., 2003; Dieu-Nosjean et al., 2008), 
renal cancer and many other tumor enti-
ties. In those studies, investigators counted 
the number of infiltrating immune cells in 
primary tumors and demonstrated, that 
patients with high T cell density have a sig-
nificant better prognosis than patients with 
low T cell density in the primary tumor. In 
colon cancer, T cell infiltrates in the pri-
mary tumor represent the strongest prog-
nostic parameter compared to the currently 
used stage-defining parameters like tumor 
size, depth of infiltration, and nodal status 
(Galon et al., 2006). However, such immu-
nological parameters are not routinely used 
in clinical practice yet. Why is this? Part of 
the reason is the difficulty to standardize 
such immunological diagnostic assess-
ments. The pathologist is used to judge cell 
density on the basis of semi-quantitative 
scaling systems, the assessment of an exact 
immune cell density in an individual patient 
means to manually count cells of interest in 
different predefined regions of tissue. This 
is very time consuming and almost impos-
sible for large sections, and there is a strong 
intra- and inter-observer variation.
To integrate immunological assessments 
into the clinical diagnostic routine, we need 
automated systems analyzing predefined 
tumor regions with sophisticated image 
analysis algorithms, dealing with all the 
challenges of cell shape diversity, cell con-
glomerates, etc. In addition to that, prog-
nostic markers are useful for the judgment 
of an individual patients risk, but they do 
not help in our decision if a given treat-
ment is going to increase an individual 
patient’s survival. Therefore we desper-
ately need markers that help to select for 
treatments, allowing to predict whether an 
individual patient is likely to benefit from a 
given treatment or dismiss treatments that 
are unlikely to be effective. With very few 
exceptions, such biomarkers have not been 
identified for the majority of tumor diseases 
(Benvenuti et al., 2007). We recently discov-
ered the correlation of T cell infiltrates at 
the invasive margin of liver metastases of 
colorectal cancer patients with response to 
chemotherapy, progression free survival 
(PFS), and overall survival (OS; Halama 
et al., 2011). Patients with an intense T cell 
infiltrate at the invasive margin of liver 
metastases had very high response rates to 
conventional chemotherapy, a significant 
better PFS and OS than patients with rela-
tive low T cell densities. Interestingly, the 
cut off values defining T cell dense versus 
T cell low tumors are very similar to the 
numbers published by Galon et al. (2006) in 
primary colon cancers defining prognosti-
cally favorable versus unfavorable tumors. 
Infiltrate density heterogeneity is compara-
ble to the situation in primary colon cancer 
(Halama et al., 2010) and T cell infiltrates 
are very heterogenic at the invasive margin 
of liver metastases. Therefore, larger tissue 
areas need to be analyzed to get reliable 
results for individual patients. Using a com-
putational image analysis system we devel-
oped an automated platform allowing high 
throughput analysis of large tissue sections. 
Sophisticated algorithms based on morpho-
logical and spectral information identified 
immune cell densities in predefined tissue 
regions recognizing and addressing the 
challenges of non-uniformly shaped cells, 
different cell size, clustering, etc. Our sys-
tem allows us now to analyze large tissue 
areas in patient samples, respecting the high 
heterogeneity of immune cell infiltrates in 
tumors. Analyzing just small tissue areas 
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(tissue microarrays have ∼0.3 mm2), there 
is a strong bias, making interpretation of the 
data impossible for individual patients and 
leading to large patient cohorts to be ana-
lyzed to produce robust data. For an indi-
vidual patient, larger tissue areas should be 
evaluated. Depending on the analyzed cell 
type, at least 3 mm2 is suitable to produce 
data that are of prognostic or predictive 
value for a single patient.
We could confirm our findings of the 
predictive significance of immune cell infil-
trates at the invasive margin of colon cancer 
liver metastases in two independent patient 
cohorts undergoing chemotherapy and we 
just started a prospective clinical trial in 
metastatic colorectal cancer patients where 
we assess cellular immune responses at the 
tumor site before and under chemotherapy 
to better understand how chemotherapy 
modulates cellular immune responses and 
how chemotherapy impacts on the immu-
nological micromilieu.
A provocative hypothesis could ques-
tion, what the main mechanism of chemo-
therapy in advanced colorectal cancer might 
be: direct tumor cell killing or modulation 
of the immunological microenvironment? 
The latter mechanism then allowing cellu-
lar immune responses to invade and attack 
tumor cells.
Chemotherapy could potentially sup-
press inhibitory immune cell functions, 
facilitating tumor-specific T cells to invade 
and attack. This aspect is supported by the 
immunosurveillance theory developed by 
R. Schreiber and others (Dunn et al., 2002, 
2004; Smyth et al., 2006). Additionally to 
that, chemotherapy induced cell death 
leads to activation of effector immune 
cells, the recognition of new antigens and 
a broad activation of the immune system, 
initially described as immunogenic cell 
death (Zitvogel et al., 2008a,b, 2011). To 
better understand the complex interplay 
of immune cell subsets in tumors, at the 
invasive margin and systemically, we need 
to monitor subpopulations like dendritic 
cells, macrophages, Th1 T cells, cytotoxic 
T cells, and natural killer cells which are 
thought to have anti-tumor effects and 
cancer-associated macrophages, myeloid 
derived suppressor cells, neutrophils, Th2 
and Th17 T cells, and FOXP3-positive 
regulatory T cells with tumor promoting 
properties (Pages et al., 2009; Zitvogel et al., 
2011).
Until now, we still treat patients with 
colorectal cancer according to their clini-
cal stage which is purely based on tumor 
infiltration depth in the colon, presence 
or absence of lymph node metastases and 
distant metastases. Immunological param-
eters that help to define the prognosis in 
colorectal cancer (Pages et al., 2005; Galon 
et al., 2006) are still not applied in the clinic. 
Especially for adjuvant treatment, there is 
great clinical need for biological/immuno-
logical markers that help to identify patients 
likely or unlikely to benefit from chemo-
therapy. Our data from the metastatic 
disease situation suggest that immune cell 
dense patients are patients more likely to 
benefit from chemotherapy. Data for the 
adjuvant situation points into a similar 
direction but has not been analyzed sys-
tematically (Morris et al., 2008). Whether 
there is also a more complex differentiation 
necessary for colorectal cancer, remains to 
be seen. Up to now, the two main groups are 
patients with dense immune cell infiltrates 
and good prognosis versus patients with low 
immune cell infiltrates and poor prognosis. 
What should we do with the patients that 
have low T cell density at the tumor site that 
have a poor prognosis and are unlikely to 
benefit from chemotherapy? Is it possible to 
induce cellular immune responses in such 
patients and convert them from poor prog-
nosis to good prognosis patients? Or define 
such immune cell infiltrates simply a more 
favorable tumor biology? To address this 
very important question, cellular immune 
responses in colon cancer patients need to 
be characterized carefully including detailed 
analysis of the immunological micromilieu 
in T cell rich versus T cell low patients, as well 
as the antigen specificity of such infiltrating 
T cells and the molecular profile – includ-
ing the mutational profile – of immune cell 
dense versus immune cell low tumors. Until 
now it is still unknown what the targets of 
prognostic relevant T cell responses in colon 
cancer are. In the past we tried to identify 
or select antigens that are more or less 
abundantly and specifically expressed by 
tumor cells. Such antigens have been used 
in the past to induce or enhance cellular 
immune responses in patients. We might 
have missed the relevant antigens that could 
very well be mutated antigens. For malig-
nant melanoma, these mutated antigens 
seem to form the largest group of antigens 
that are detected by T cells (Lennerz et al., 
2005). Robert Schreiber and his colleagues 
have shown in mouse sarcoma models 
that spontaneous T cell responses leading 
to tumor rejection or at least equilibrium 
state of immunosurveillance are directed 
against mutated antigens encoded by genes 
that have no obvious role in the respective 
tumor biology, most likely representing 
passenger mutations. If this is similar to 
the situation in humans, it could very well 
be that we need to analyze the spectrum of 
tumor mutations individually, test which of 
them are recognized by the individual host 
and use such target antigens for individual 
immunotherapeutical intervention.
There is great need to take this in con-
sideration and incorporate immunologi-
cal characterization of individual tumor 
diseases into the clinical routine. Knowing 
about the individual tumor biology and 
individual tumor immunology, we hope-
fully can design more intelligent and for the 
individual patient more effective treatment 
strategies. To realize this, we need to invest 
a lot more resources into diagnostic pro-
cedures, but such resources will be worth 
investing in as they definitely will allow to 
avoid ineffective, but expensive treatments.
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